Literature DB >> 15551131

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.

Damian Wild1, Helmut R Mäcke, Beatrice Waser, Jean Claude Reubi, Mihaela Ginj, Helmut Rasch, Jan Müller-Brand, Michael Hofmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15551131     DOI： 10.1007/s00259-004-1697-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.

Authors:  M Hofmann; H Maecke; R Börner; E Weckesser; P Schöffski; L Oei; J Schumacher; M Henze; A Heppeler; J Meyer; H Knapp
Journal:  Eur J Nucl Med       Date:  2001-10-31

Review 2.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.

Authors:  Jean Claude Reubi; Beatrice Waser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-18       Impact factor: 9.236

3.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Authors:  Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236
  3 in total
  64 in total

Review 1.  Somatostatin receptor PET ligands - the next generation for clinical practice.

Authors:  Elin Pauwels; Frederik Cleeren; Guy Bormans; Christophe M Deroose
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

Authors:  Yodphat Krausz; Nanette Freedman; Rina Rubinstein; Efraim Lavie; Marina Orevi; Sagi Tshori; Asher Salmon; Benjamin Glaser; Roland Chisin; Eyal Mishani; David J Gross
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

3.  (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Authors:  Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03       Impact factor: 9.236

4.  Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients.

Authors:  Chi Long Ho
Journal:  Nucl Med Mol Imaging       Date:  2015-03-25

5.  18F-DOPA PET/CT and neuroendocrine tumours.

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05       Impact factor: 9.236

Review 6.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

7.  What can gallium-68 PET add to receptor and molecular imaging?

Authors:  Adil Al-Nahhas; Zarni Win; Teresa Szyszko; Aviral Singh; Sameer Khan; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

Review 8.  Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  David Taïeb; Philippe Garrigue; Manuel Bardiès; Ahmad Esmaeel Abdullah; Karel Pacak
Journal:  PET Clin       Date:  2015-07-08

9.  68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors.

Authors:  C Pettinato; A Sarnelli; M Di Donna; S Civollani; C Nanni; G Montini; D Di Pierro; M Ferrari; M Marengo; C Bergamini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-14       Impact factor: 9.236

Review 10.  Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.

Authors:  David Taïeb; Arthur Varoquaux; Clara C Chen; Karel Pacak
Journal:  Semin Nucl Med       Date:  2013-11       Impact factor: 4.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.